论文部分内容阅读
数十年来对转移乳腺癌联合化疗方案进行了彻底的研究,联合化疗在其他晚期癌症中存在根治作用,是驱使这一不懈研究的动力之一。但在乳腺癌中这一方法并未取得类似生殖细胞瘤或淋巴瘤那样的临床结果。近期报道的ECOG1193研究显示,联合化疗并不比序贯单独用药具有明显优势。准确意义上要决定哪些病人该接受联合化疗或单药治疗,目前临床肿瘤学艺术与科学两方面具有同等重要作用。目前还缺乏能对这一选择进行指导的
For decades, a thorough study of combined chemotherapy for metastatic breast cancer has been conducted, and combination chemotherapy has a radical effect on other advanced cancers and is one of the motivators driving this tireless study. However, this method in breast cancer did not achieve the same clinical results as germ cell tumors or lymphoma. Recently reported ECOG1193 study shows that combination chemotherapy is not as clear as sequential single drug treatment. In the exact sense, to decide which patients should receive combined chemotherapy or monotherapy, clinical oncology science and science are equally important. There is still a lack of guidance on this option